MONT-SAINT-GUIBERT, Belgium, Oct. 6, 2025 — Nyxoah SA announced that the first U.S. commercial patients have been implanted with the Genio® system, marking the official start of the therapy’s U.S. launch following its FDA Premarket Approval in August 2025. The milestone demonstrates strong physician demand, completed payer authorizations, and early reimbursement coverage, signaling rapid adoption for this novel therapy for obstructive sleep apnea (OSA).
Science Significance
The Genio system is a leadless, battery-free, bilateral neurostimulation device designed to activate upper airway muscles and prevent airway collapse during sleep. It differs from existing hypoglossal nerve stimulation therapies by eliminating the need for implanted batteries or leads, reducing surgical complexity and patient burden. Clinical trials such as BETTER SLEEP and DREAM IDE demonstrated significant reductions in apnea-hypopnea index (AHI) and improved sleep quality, establishing Genio as a breakthrough in sleep-disordered breathing treatment.
Regulatory Significance
Following positive pivotal study results, the U.S. FDA granted Premarket Approval (PMA) for Genio as a prescription-only implantable medical device. The system had already received CE Mark approval in 2019 and an expanded indication for Complete Concentric Collapse (CCC) patients — a population contraindicated for competing devices. These approvals affirm regulatory confidence in Genio’s safety, efficacy, and engineering design, reinforcing its standing as a next-generation sleep therapy solution.
Business Significance
Advertisement
The commercial rollout marks Nyxoah’s entry into the U.S. sleep medicine market, one of the largest globally, with an estimated 25 million Americans affected by OSA. The company reported strong initial interest from surgeons, with numerous centers already trained and performing implants. Broad reimbursement from major payors, including CMS, positions Nyxoah for sustained growth and commercial scalability across the U.S. healthcare network.
Patients’ Significance
OSA affects millions of adults, contributing to cardiovascular disease, metabolic disorders, and decreased quality of life. For patients who cannot tolerate traditional CPAP therapy, the Genio system offers a minimally invasive, fully implantable, and battery-free alternative that restores natural breathing patterns during sleep. Early U.S. experiences have shown high patient satisfaction and rapid postoperative recovery, emphasizing its real-world benefit.
Policy Significance
The FDA’s approval and early payer coverage reflect growing policy support for innovative, minimally invasive medical technologies that reduce long-term healthcare costs and improve adherence. With OSA linked to major comorbidities, encouraging adoption of next-generation therapies like Genio aligns with public health priorities in sleep medicine and chronic disease prevention.
The first U.S. Genio implants mark a major step forward for Nyxoah and the broader sleep health community. Combining engineering innovation, regulatory achievement, and patient-focused design, the Genio system sets a new standard in sleep apnea therapy—bridging the gap between advanced science and accessible, life-changing treatment.
Source: Nyxoah press release
